Value of the detection of BRAFV600E gene mutation and protein expression in auxiliary cytological diagnosis of papillary thyroid carcinoma
10.3760/cma.j.issn.1673-0860.2019.01.005
- VernacularTitle: BRAFV600E基因及蛋白检测细针穿刺标本对辅助细胞学诊断甲状腺乳头状癌的价值
- Author:
Huan ZHAO
1
;
Huiqin GUO
1
;
Zhihui ZHANG
1
;
Jian CAO
1
;
Linlin ZHAO
1
;
Yue SUN
1
;
Cong WANG
1
;
Ting XIAO
2
Author Information
1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Thyroid neoplasms;
Carcinoma, papillary;
Proto-oncogene proteins B-raf;
Biopsy, fine-needle;
Cytological techniques
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2019;54(1):18-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the utility of the BRAFV600E mutation detection in different cytoloy categories and to determine if the VE1 antibody can serve as a screening tool for the detection of BRAFV600E mutation in thyroid fine needle aspiration (FNA) specimens.
Methods:A total of 273 FNA residual specimens were collected. BRAFV600E testing was performed on these liquid-based specimens. And also 78 specimens with enough residual cells were stained with VE1 antibody. Comparisons of molecular and immunocytochemistry results with clinicopathological outcomes were performed. SPSS 17.0 software was used to analyze the data.
Results:There were 70 indeterminated diagnoses in 273 cases with FNAs. Fifty-eight cases were proven to be papillary thyroid carcinoma (PTC) by histology, including 9 cases of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 3 cases of follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), and 46 cases of suspicious for malignancy (SM). BRAFV600E analysis detected PTC in 3 of 9 cases with AUS/FLUS, and in 31 (67.4%) of 46 cases with SM. The sensitivity of immunostaining with VE1 antibody was 62.8%(27/43) and the specificity was 91.4% (32/35). VE1 expression showed moderately concordance with the molecular mutation (κ=0.524, P<0.001).
Conclusions:Additional BRAFV600E detecting can improve the diagnostic efficacy for PTC in AUS/FLUS and SM. VE1 expression may be an alternative method for BRAFV600E detecting when molecular detecting is unavailable.
